Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54
Fate Therapeutics insiders have sold stock over the past year, with the largest sale by President Bahram Valamehr for US$54k at US$1.88 per share, which is below the current market price of US$2.92. Despite the company's stock seeing a 21% rise recently, insiders have not purchased any shares, and their overall ownership is relatively low at 1.5%. This insider selling and lack of buying, combined with low insider ownership, suggests caution regarding the stock's valuation.
Fate Therapeutics to show early FT819 data in systemic sclerosis
Fate Therapeutics (NASDAQ:FATE) will present preliminary Phase 1 clinical data for its off-the-shelf CAR T-cell candidate FT819 in systemic sclerosis (SSc) at the ISSCR 2026 Annual Meeting. Early data from four treatment-refractory patients showed all achieved rCRISS ≥25 and meaningful mean mRSS improvement at 3 months with a clean safety profile, including no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths. The company plans a Phase 2 potentially registrational trial in lupus nephritis, indicating broader autoimmune disease development.
Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting
Fate Therapeutics announced preliminary clinical data from its FT819 off-the-shelf CAR T-cell product candidate for Systemic Sclerosis (SSc) will be presented at the ISSCR 2026 Annual Meeting. The data from the first four SSc patients showed encouraging clinical activity and a well-tolerated safety profile, even with less-intensive or no conditioning chemotherapy. This supports the continued advancement of FT819 as an outpatient CAR T-cell therapy for SSc and its evaluation in Systemic Lupus Erythematosus.
Fate Therapeutics to Present Preliminary Clinical Data of
Fate Therapeutics, Inc. announced that preliminary clinical data for its off-the-shelf CAR T-cell product candidate, FT819, will be presented at the ISSCR 2026 Annual Meeting. The data, focusing on the Systemic Sclerosis arm of its Phase 1 trial, shows favorable tolerability and encouraging clinical activity with less-intensive or no conditioning chemotherapy. This supports FT819's continued development as an outpatient CAR T-cell therapy for Systemic Sclerosis and potentially for Systemic Lupus Erythematosus.
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in several investor conferences in the third quarter of 2026. Management will attend the Leerink Partners Therapeutics Forum, Wells Fargo 21st Annual Healthcare Conference, 12th Annual Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The company specializes in iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Fate Therapeutics lines up four investor conferences in Q3
Fate Therapeutics (NASDAQ:FATE) announced its management will participate in four investor conferences during the third quarter of 2026, including events hosted by Leerink Partners, Wells Fargo, Cantor Fitzgerald, and H.C. Wainwright. These participations aim to increase the company's visibility and provide updates on its iPSC-derived cellular immunotherapy pipeline. Webcasts of presentations or fireside chats will be available on the company's investor relations website.
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics, Inc. announced its participation in several investor conferences during the third quarter of 2026, including the Leerink Partners Therapeutics Forum, Wells Fargo Healthcare Conference, Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright Global Investment Conference. The clinical-stage biopharmaceutical company will present or hold fireside chats at these events, making webcasts available on its investor relations website. Fate Therapeutics focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences
Fate Therapeutics, Inc. (NASDAQ: FATE) announced its participation in several investor conferences during the third quarter of 2026, including the Leerink Partners Therapeutics Forum, Wells Fargo 21st Annual Healthcare Conference, 12th Annual Cantor Fitzgerald Global Healthcare Conference, and H.C. Wainwright 28th Annual Global Investment Conference. The clinical-stage biopharmaceutical company will discuss its pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases. Webcasts of any presentations will be available on the company's website.
FATE Stock Price and Chart — NASDAQ:FATE
This article provides an overview of Fate Therapeutics, Inc. (FATE) stock, including its current price, key financial statistics, and performance. It details the company's business in developing cellular immunotherapies for cancer and immune disorders, lists its founding members and headquarters, and includes various investor insights and analyst ratings. The report also addresses frequently asked questions regarding the stock's price, volatility, market capitalization, earnings, and dividend policy.
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index
Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 3000E Index. This announcement follows similar removals from the Russell 2000 Index and Russell 2000 Value Benchmark on the same day. The company, a clinical-stage biopharmaceutical firm, specializes in iPSC-derived cellular immunotherapies.
Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders
Fate Therapeutics Inc. (FATE) stock increased by 11.76% after releasing positive early Phase 1 data for its FT836 cancer treatment in KRAS wild-type metastatic colorectal cancer, showing meaningful tumor reductions without conditioning chemotherapy. The company's strategic profile is further strengthened by the appointment of a senior commercial leader and upcoming meetings with Piper Sandler. While FATE is a pre-revenue biotech with negative profitability, its strong balance sheet provides several years of cash runway, and the market appears to be heavily discounting pipeline risk despite positive clinical developments.
Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index
Fate Therapeutics, Inc. (NasdaqGM:FATE) has been removed from the Russell 2000 Dynamic Index. This news was published on June 28, 2026, at 08:53 pm EDT by S&P Capital IQ. The company is a clinical-stage biopharmaceutical firm focused on developing off-the-shelf, multiplexed-engineered, iPSC-derived cellular immunotherapies.
Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History
This page provides a comprehensive overview of Fate Therapeutics Inc (FATE) stock, including its current price, historical data, news, and key financial metrics. It details the company's financial performance, analyst ratings, valuation, and market statistics. FATE is a clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and autoimmune disorders.
Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T)
This article provides financial actuals and estimates for Fate Therapeutics, Inc. (F6T) traded on the Dusseldorf Stock Exchange. It covers income statement, balance sheet, cash flow, and valuation metrics, along with analyst forecasts for its stock price. The article also details past earnings, revenue, net income, employee count, and upcoming earnings dates, emphasizing that F6T does not pay dividends.
Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Fate Therapeutics Inc (FATE), noting its current valuation score is 7.14, ranking 255 out of 387 in the Biotechnology & Medical Research industry. It gives the stock's current P/E ratio as -1.72, which is significantly below its recent high, but points out that P/B, P/S, and P/CF relevant data have not been disclosed by the company. The article includes current stock pricing and market capitalization information for FATE.
Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T)
This article provides an overview of Fate Therapeutics, Inc. (F6T) listed on the Tradegate Exchange, including its financial actuals, analyst estimates, and frequently asked questions. It details various financial metrics such as earnings, revenue, net income, EBITDA, and future earnings estimates, alongside historical stock performance data. The article also touches upon the company's employee count and next earnings report date.
Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE)
This article provides a comprehensive overview of Fate Therapeutics, Inc. (NASDAQ:FATE), including its current stock price, historical performance, and analyst forecasts. It details financial actuals and estimates for income statements, balance sheets, and cash flow, alongside key metrics like market capitalization, EBITDA, and earnings reports. The information is presented to help investors understand the company's financial health and stock potential.
Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE
This page from TradingView displays financial information for Fate Therapeutics, Inc. (NASDAQ: FATE), specifically focusing on its enterprise value to revenue forward metric. The content indicates that the market is closed and provides general navigation and company information for TradingView, rather than deep financial analysis of FATE.
Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE
This article displays the "Price to earnings forward" for Fate Therapeutics, Inc. (NASDAQ: FATE) as part of a financial overview on TradingView. It indicates that the market was closed at the time of viewing, with no trades, and offers various financial and community data points related to the company.
FATE Forecast — Price Target — Prediction for 2027
This article provides a forecast for Fate Therapeutics, Inc. (FATE) stock, including analyst price targets and predictions for 2027. It details recent stock performance, historical highs and lows, volatility metrics, market capitalization, and upcoming earnings dates. Additionally, it addresses frequently asked questions about FATE's stock and offers guidance on how to interpret technical analysis.
Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities
Mizuho Securities has maintained a Buy rating on Fate Therapeutics (FATE) with a price target of $8.00. This comes despite the company reporting a quarterly revenue of $1.3 million and a GAAP net loss of $31.21 million for the quarter ending March 31, and negative insider sentiment with recent share sales. The analyst consensus on FATE is currently a Moderate Buy with an average price target of $5.24.
Fate Therapeutics Inc (FATE) Institutional Confidence
Fate Therapeutics Inc (FATE) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding stands at 79.47%, a 34.82% decrease quarter-over-quarter. The largest institutional shareholder is Bill Nygren | OAKMX, holding 5.22M shares, which represents 8.87% of shares outstanding.
Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Fate Therapeutics Inc (FATE), detailing its current price momentum, support and resistance levels, and indicator and moving average readings. It notes that the stock is currently trading between resistance at $2.63 and support at $1.54, suggesting range-bound swing trading. While individual indicators like TRIX show a 'Sell' signal, the overall technical rating based on moving averages and other indicators is 'Neutral'.
Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Fate Therapeutics Inc's (FATE) dividend and stock split history, noting that the company has distributed $0.00 in dividends over the past five years. It indicates that there is no historical data available for either dividends or stock splits for FATE. The content is hosted on TradingKey, a platform offering market data and analysis.
Fate Therapeutics Shareholders Back Directors and Governance Plans
Fate Therapeutics shareholders have elected three Class I directors and ratified Ernst & Young LLP as their independent auditor. Investors also approved executive compensation and an amendment to the stock option plan, indicating support for the company's governance and compensation strategies. Despite weak financial performance, the company shows positive technical trends and pipeline progress.
Director Laura Hamill files initial Form 3 for FATE Therapeutics (FATE)
Laura Hamill, a director at FATE Therapeutics Inc. (FATE), has filed an initial Form 3, which is a required statement of beneficial ownership for company insiders. This filing indicates her status as an insider but reports no current transactions or derivative positions, serving primarily as an administrative disclosure. The document outlines her beneficial ownership of non-derivative securities and confirms she holds no derivative securities at this time.
Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06
Fate Therapeutics director Michael Stewart Lee was granted 87,900 stock options as compensation for his board service. These options allow the purchase of common shares at an exercise price of $2.06 per share, expiring in June 2036, and will vest in full by June 12, 2027, or the company's 2027 annual stockholders’ meeting, contingent on his continued service. The grant is held by Lee as a nominee for Redmile Group, LLC, which holds the economic and voting rights.
Director Laura Hamill receives 175,800 Fate Therapeutics (FATE) stock options
Fate Therapeutics director Laura Hamill has been granted 175,800 stock options with an exercise price of $2.06 per share, expiring in June 2036. This grant is part of the company's non-employee director compensation policy and will vest in 36 equal monthly installments beginning June 12, 2026, contingent on her continued service. Following this transaction, Hamill directly holds 175,800 stock options.
Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06
Fate Therapeutics director Yuan Xu was granted 87,900 stock options at an exercise price of $2.06 per share as part of the company's non-employee director compensation policy. These options will vest on the earlier of June 12, 2027, or the 2027 annual stockholder meeting, contingent on Xu's continued board service. This transaction is a routine equity grant and not an open-market purchase or sale.
[8-K] FATE THERAPEUTICS INC Reports Material Event
Fate Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 12, 2026. Stockholders approved a third amendment to the company’s 2022 Stock Option and Incentive Plan, increasing available shares by 7,000,000, elected three Class I directors, and ratified Ernst & Young LLP as the independent registered public accounting firm. Additionally, a non-binding advisory vote approved the compensation of the named executive officers.
Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike
Fate Therapeutics director Robert S. Epstein was granted 87,900 stock options with an exercise price of $2.06 per share, expiring on June 12, 2036. This grant is part of the company's Amended and Restated Non-Employee Director Compensation Policy, vesting on the earlier of June 12, 2027, or the 2027 Annual Meeting of Stockholders, provided Epstein continues his board service. Following this transaction, Epstein directly holds 87,900 options.
Fate Therapeutics (FATE) director receives 87,900 stock options award
Shefali Agarwal, a director at Fate Therapeutics (FATE), has been granted 87,900 stock options with an exercise price of $2.06 per share, expiring on June 12, 2036. The options will vest and become exercisable on the earlier of June 12, 2027, or the company's 2027 Annual Meeting of Stockholders, contingent on her continued board service. This grant is part of the company's Non-Employee Director Compensation Policy.
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics has appointed Laura Hamill, a global senior executive with extensive commercial and strategic management experience in the biopharmaceutical industry, to its Board of Directors. Her appointment is expected to be invaluable as the company advances its cell therapy programs toward later-stage clinical development and prepares for commercialization. Hamill previously served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., and held significant roles at Amgen, bringing deep expertise in strategic planning, market development, and product launches.
Fate Therapeutics Inc Stock (US3025491025): valuation focus as clinical-stage biotech trades near lo
Fate Therapeutics Inc (FATE) is a clinical-stage biopharmaceutical company trading near its 52-week lows, prompting a valuation focus from investors. The company, which specializes in off-the-shelf cell therapies for cancer and immune disorders, relies on collaboration income and its cash balance to fund R&D, having restructured after a terminated partnership with Johnson & Johnson. Investors are closely monitoring its cash runway, clinical pipeline, and potential for future partnerships or financing rounds, as traditional valuation metrics are not applicable to this pre-revenue biotech firm.
Fate Therapeutics Appoints Laura Hamill to Board of Directors
Fate Therapeutics (NASDAQ: FATE) has appointed Laura Hamill, a seasoned global commercial operations leader, to its Board of Directors. Ms. Hamill brings extensive experience in launching and scaling biopharmaceutical products, which will be invaluable as Fate Therapeutics advances its pipeline of iPSC-derived cellular immunotherapies toward later-stage development and commercialization. Her background at Gilead Sciences and Amgen, where she oversaw multi-billion dollar revenues and led global commercial organizations, positions her as a key asset for the company's future growth and market entry.
Executive who oversaw $22B at Gilead joins Fate cell therapy board
Fate Therapeutics (NASDAQ:FATE) has appointed Laura Hamill, a biopharmaceutical industry veteran with over 30 years of commercial leadership experience, to its Board of Directors. Hamill previously served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, overseeing approximately $22 billion in annual revenue and 2,500 employees. Her appointment is expected to bolster Fate Therapeutics' efforts as it advances its iPSC-derived cell therapy pipeline toward commercialization, leveraging her expertise in strategic planning, market access, pricing, and commercial launches.
FATE SEC Filings - Fate Therapeutic 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Fate Therapeutics (FATE) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It details recent filings such as a CFO's beneficial ownership statement, an S-8 registration for employee benefit plans, board changes including a new CFO appointment, and a corporate restructuring plan to reduce costs. The article highlights AI-generated summaries, impact scoring, and sentiment analysis for each filing.
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT
H.C. Wainwright has reiterated a "Buy" rating and a $7.00 price target for Fate Therapeutics (FATE) following promising Phase 1 data for its lead cell therapy program, FT819, presented at the annual EULAR meeting. The data demonstrated a sustained clinical improvement in systemic lupus erythematosus patients with bendamustine conditioning and supported the upcoming Phase 2 RECLAIM-LN trial. Fate Therapeutics is a clinical-stage biopharmaceutical company focusing on immunotherapies for cancer and immune disorders.
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT
H.C. Wainwright reiterated a "Buy" rating and a $7.00 price target for Fate Therapeutics (FATE) after the company presented positive Phase 1 data for its lead off-the-shelf cell therapy program, FT819, at the annual EULAR meeting. The data demonstrated deeper and more consistent B-cell depletion in systemic lupus erythematosus patients, supporting the potential for outpatient administration and advancing to the Phase 2 RECLAIM-LN trial. Fate Therapeutics is a clinical-stage biopharmaceutical company focused on cellular immunotherapies for cancer and immune disorders.
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6
Piper Sandler has reiterated its Buy rating for Fate Therapeutics (FATE.US) and maintained a target price of $6. The firm's decision reflects continued confidence in the company's prospects. This analyst rating suggests that Piper Sandler sees significant upside potential for Fate Therapeutics stock.
Fate Therapeutics Showcases Data from FT819 and FT839
Fate Therapeutics presented promising clinical data on its off-the-shelf CAR T-cell therapy candidates, FT819 and FT839, at the European Congress of Rheumatology annual meeting. FT819 demonstrated rapid and sustained clinical improvement and a favorable tolerability profile in lupus patients, alongside effective B-cell depletion and reset. Preclinical data for FT839 showed comprehensive elimination of activated immune cells in rheumatoid arthritis patient samples without conditioning chemotherapy, indicating its potential for broad autoimmune disease treatment.
Fate Therapeutics (NASDAQ: FATE) details FT819, FT836 data and cash runway into 2028
Fate Therapeutics provided updates on its off-the-shelf cell therapy pipeline, highlighting data for FT819 in autoimmune diseases and FT836 in cancer. The company announced plans for a potentially registrational Phase 2 trial for FT819 in lupus nephritis, targeting 53 patients with enrollment beginning in late 2026. Financially, Fate Therapeutics reported a cash runway into 2028, supported by approximately $174.8 million in cash and a 20% reduction in operating expenses during Q1 2026.
Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash
Fate Therapeutics (FATE) has released an updated corporate presentation ahead of EULAR 2026, detailing significant progress in its clinical programs. The update highlights positive safety and clinical improvements in the FT819 Phase 1 trial, with Phase 2 enrollment planned for the second half of 2026. Additionally, the FT836 pan–solid tumor Phase 1 study is actively enrolling, showing preliminary anti-tumor activity.
Small lupus trial tests off-the-shelf CAR T with same-day discharge
Fate Therapeutics presented new Phase 1 data for its off-the-shelf CAR T-cell candidate FT819 in systemic lupus erythematosus (SLE) and preclinical data for FT839 at EULAR 2026. FT819 showed favorable tolerability, deep B-cell depletion, improved disease activity, and reduced glucocorticoid use in refractory SLE patients, including outpatient administration with same-day discharge. Preclinical FT839 data demonstrated selective elimination of activated immune cells in rheumatoid arthritis samples without conditioning chemotherapy, highlighting its potential for broad autoimmune disease treatment.
Fate Therapeutics Showcases Data from FT819 and FT839
Fate Therapeutics presented promising data for its off-the-shelf CAR T-cell therapies, FT819 and FT839, at the European Congress of Rheumatology annual meeting. FT819 demonstrated rapid and sustained clinical improvement with a favorable tolerability profile in 21 systemic lupus erythematosus (SLE) patients, including successful outpatient administration and sustained B-cell depletion. Preclinical data for FT839, a dual-CAR T-cell product, showed comprehensive elimination of activated immune cells in rheumatoid arthritis samples without the need for conditioning chemotherapy, suggesting broad potential for various autoimmune diseases.
Fate Therapeutics presents autoimmune therapy data at EULAR
Fate Therapeutics (NASDAQ:FATE) revealed clinical and preclinical data for its CAR T-cell therapy candidates, FT819 and FT839, at the European Congress of Rheumatology. The company presented promising results for FT819 in systemic lupus erythematosus patients, showing good safety and reduced disease activity. Fate Therapeutics also plans to initiate a Phase 2 trial for lupus nephritis and continues to advance its CAR T-cell therapies for autoimmune diseases.
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
Fate Therapeutics presented promising data for its off-the-shelf CAR T-cell therapy candidates, FT819 and FT839, at the European Congress of Rheumatology annual meeting. FT819 demonstrated rapid and sustained clinical improvement with a favorable tolerability profile in 21 systemic lupus erythematosus (SLE) patients, including successful outpatient administration and deep B-cell depletion. Preclinical data for FT839, a dual-CAR T-cell therapy targeting CD19 and CD38, showed potent and selective elimination of activated immune cells in rheumatoid arthritis patient samples without the need for conditioning chemotherapy.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced that it granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two new non-executive employees. These grants were approved by the Compensation Committee and issued as an inducement for their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, conditional on continued employment.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced the granting of restricted stock units (RSUs) representing 67,300 shares of common stock to two new non-executive employees on June 1, 2026. These inducement awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. Fate Therapeutics is a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases.
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. announced it granted restricted stock units (RSUs) representing 67,300 shares of its common stock to two new non-executive employees on June 1, 2026. These inducement awards were approved by the Compensation Committee and granted under the Company’s Amended and Restated Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, contingent on continuous employment.
